Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor (Q26745621)

Surgery for Obesity and Related Diseases

Europe PubMed Central

title

Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor (English)

0 references

0 references

1

0 references

Sten Madsbad

object named as

Sten Madsbad

series ordinal

2

0 references

language of work or name

English

0 references

publication date

July 2016

0 references

published in

0 references

volume

12

0 references

issue

6

0 references

page(s)

1236-42

0 references

cites work

Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Critical role for peptide YY in protein-mediated satiation and body-weight regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

INCREASED GUT GLUCAGON RELEASE AS PATHOGENETIC FACTOR IN REACTIVE HYPOGLYCqMIA?

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

FXR is a molecular target for the effects of vertical sleeve gastrectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Control of type 2 diabetes after 1 year of laparoscopic adjustable gastric banding in the helping evaluate reduction in obesity (HERO) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Gastric bypass and duodenal and gastric feeding: a comment to Hansen et al

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

The physiology underlying Roux-en-Y gastric bypass: a status report

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Extrapancreatic Glucagons

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Immunoreactive gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Enhanced Intestinal Motility during Oral Glucose Tolerance Test after Laparoscopic Sleeve Gastrectomy: Preliminary Results Using Cine Magnetic Resonance Imaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Plasma Enteroglucagon after Jejunoileal Bypass with 3:1 or 1:3 Jejunoileal Ratio

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021

The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.SOARD.2016.02.033

7 January 2021